Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS) from its SEC filings: 2025 revenue $7.8 million (-58% vs the year before), net margin -830%, free cash flow -$47.2 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $7.8 million |
| Revenue growth | -58% |
| Net income | -$64.9 million |
| Net margin | -829.6% |
| Free cash flow | -$47.2 million |
| Diluted EPS | $-0.53 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -8% |
| Cash | $19.2 million |
| Long-term debt | $10.7 million |
| Share count, 1 year | +36% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.